Just checked ANI's latest quarterly results and the numbers are pretty solid. The pharma company beat expectations with $247M in revenue, up nearly 30% year-over-year. EPS came in at $2.33 versus the $1.99 consensus estimate, so that's a solid beat too. What caught my eye is how ANI performed across different segments. Their rare disease and brand portfolio pulled in $143.59M, which was a 34% jump compared to last year. The generic pharma side also delivered, hitting $100.76M and crushing analyst estimates by over $14M. Cortrophin Gel and the newer rare disease products like ILUVIEN and YUTIQ are clearly driving growth. Not everything was perfect though - ANI came in slightly light on the Cortrophin Gel revenue forecast, but the generic drugs segment more than made up for it. The stock has been down 5.9% over the past month, underperforming the broader market, which seems like it might be an overreaction given these solid earnings. If ANI can keep this momentum going in rare diseases and generics, could be an interesting play to watch.